Who’s “we”?

This article (free with free account) is making the rounds and getting some attention. The post below addresses the issues raised. (originally posted on 10/31/2014) ==================================== This article has been forwarded to me by several people. Its author has been writing a series of articles that seek to redefine addiction and recovery. As Eve Tushnet recently … Continue reading Who’s “we”?

ASAM president also medical director for drug company

I missed this a while back. Turns out that ASAM's president works for a buprenorphine manufacturer. Stuart Gitlow, M.D., is the president of the American Society of Addiction Medicine (ASAM) and also medical director — as a consultant — for Orexo, which makes Zubsolv, a newly approved buprenorphine-naloxone medication (see ADAW, July 15). The first public … Continue reading ASAM president also medical director for drug company

DSM 5 Substance Use Disorders: A Concise Summary

Terry Gorski has a nice summary of substance use disorders in the DSM-5. Here's his analysis at the end of the post: The DSM 5 is criticized for combining the the DSM IV categories of substance dependence (addiction marked by a pattern of compulsive use or loss of control) and substance abuse disorders (using in … Continue reading DSM 5 Substance Use Disorders: A Concise Summary

NAATP launches counteroffensive to medication push

This is very welcome news: Frustrated that medication-assisted treatment is coming across as the addiction field’s standard of care simply because drug company studies are dominating the research landscape, a group of some of the most prominent leaders in treatment administration is vowing to fight back. These leaders have enlisted the help of another heavy … Continue reading NAATP launches counteroffensive to medication push